RhumbLine Advisers’s Cidara Therapeutics CDTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-26,695
| Closed | -$5.9M | – | 4106 |
|
|
2025
Q4 | $5.9M | Buy |
26,695
+3,410
| +15% | +$551K | ﹤0.01% | 1312 |
|
|
2025
Q3 | $2.23M | Sell |
23,285
-1,673
| -7% | -$107K | ﹤0.01% | 1848 |
|
|
2025
Q2 | $1.22M | Buy |
+24,958
| New | +$600K | ﹤0.01% | 2152 |
|
|
2021
Q2 | – | Sell |
-1,392
| Closed | -$74K | – | 3006 |
|
|
2021
Q1 | $74K | Sell |
1,392
-225
| -14% | -$11.1K | ﹤0.01% | 2960 |
|
|
2020
Q4 | $65K | Buy |
1,617
+439
| +37% | +$21.8K | ﹤0.01% | 3006 |
|
|
2020
Q3 | $67K | Sell |
1,178
-219
| -16% | -$15.5K | ﹤0.01% | 2934 |
|
|
2020
Q2 | $103K | Buy |
+1,397
| New | +$90.5K | ﹤0.01% | 2962 |
|
|
2017
Q2 | – | Sell |
-695
| Closed | -$108K | – | 2928 |
|
|
2017
Q1 | $108K | Buy |
695
+31
| +5% | +$5.44K | ﹤0.01% | 2771 |
|
|
2016
Q4 | $138K | Sell |
664
-162
| -20% | -$33.7K | ﹤0.01% | 2759 |
|
|
2016
Q3 | $189K | Buy |
826
+122
| +17% | +$28.2K | ﹤0.01% | 2697 |
|
|
2016
Q2 | $145K | Buy |
+704
| New | +$170K | ﹤0.01% | 2839 |
|
RhumbLine Advisers's CDTX Position: Q1 2026 in Review
RhumbLine Advisers sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 26,695 shares — an estimated $5.9M sold.
RhumbLine Advisers first reported a position in CDTX in Q2 2016 and held it in 11 quarters. The position peaked at $5.9M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.
- RhumbLine Advisers reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
- RhumbLine Advisers sold 26,695 Cidara Therapeutics shares in Q1 2026, an estimated $5.9M.
- RhumbLine Advisers first reported a position in Cidara Therapeutics in Q2 2016 and held it in 11 quarters.
- RhumbLine Advisers's Cidara Therapeutics position peaked at $5.9M in Q4 2025.
- 0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.
Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.